Please login to the form below

Not currently logged in
Email:
Password:

TriCor

This page shows the latest TriCor news and features for those working in and with pharma, biotech and healthcare.

AbbVie is not looking at another big acquisition, says CEO

AbbVie is not looking at another big acquisition, says CEO

Despite a tougher competitive environment Humira continued to grow strongly, with sales up almost 18% to $3.26bn, although the lipid-lowering franchise based on Tricor/TriLipix (fenofibrate) and Niaspan (niacin)

Latest news

  • AbbVie sales jump on strong Humira gains AbbVie sales jump on strong Humira gains

    AbbVie's sales gains came despite the continuing impact of the loss of patent protection for cholesterol-lowering drug TriCor (fenofibrate), which fell 66 per cent to $153m as generic competition

  • AbbVie said to be planning major salesforce cuts in US AbbVie said to be planning major salesforce cuts in US

    start of generic competition to cholesterol-lowering drugs TriCor (fenofibrate) and Niaspan (niacin). ... According to AbbVie's 2012 report, combined sales of TriCor and Trilipix totalled $1.1bn, while Niaspan contributed $911m, with all sales derived

  • Abbott reports flat Q2 net profit

    Cholesterol treatment, TriCor/Trilipix (fenofibrate) also saw improved growth, with sales increasing 15.6 per cent to £388m.

  • Abbott to purchase Solvay pharma

    TriCor uses the active ingredient fenofibrate and accounts for about 20 per cent of Brussels-based Solvay's pharmaceutical sales. ... In 2011 TriCor faces generic competition and Abbott is seeking regulatory approval to market TriLipix in combination

  • Elan and J&JPRD submit NDA for novel Invega reformulation

    Four US marketed products currently use NanoCrystal Technology: lipid-lowering TriCor (fenofibrate), which is marketed by Abbott and Solvay; cachexia treatment Megace ES (megestrol), which is marketed by Par Pharmaceutical; immunosuppressant

More from news
Approximately 0 fully matching, plus 7 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Makara Health

Independent healthcare communications agency with a passion to develop inspirational ideas that create sustained and positive change. Whether it is...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics